A three-year $2.9 million grant from the Department of Defense Translational Research Program has been awarded to Jeffrey Chamberlain, Julie Crudele, and David Mack. The project will explore applying spit-intein technology to produce safer constructs for Duchenne Muscular Dystrophy gene therapy.
Neuromuscular Disease Research Group
University of Washington, Institute for Stem Cell and Regenerative Medicine